KRAS and non-small cell lung carcinoma: For example, STK11, B2M, and EGFR mutations or MDM2 amplification were associated with poor responsiveness or even hyper-progressive disease (HPD) (9, 10), whereas TP53, KRAS, and POLE mutations or KP (co-mutations of KRAS and TP53) molecular sub-type were positively related with ICB response in advanced NSCLC (11, 12).